UNSPSC 51312307: Chlorphenoxamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H22ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5I159322PY, chemically known as 2-((p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy)-n,n-dimethylethylamine hydrochloride but more generally known as chlorphenoxamine hydrochloride, which bears US NIH Compound Identifier 11223. European Medicines Agency schedules Chlorphenoxamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01250MIG.

UNSPSC 51312307 Chlorphenoxamine hydrochloride, a Commodity-tier code, appears in state and local procurement activity primarily as part of broader pharmaceutical and drug-management purchasing rather than as a standalone product line. Recent opportunities under this code do not center on chlorphenoxamine hydrochloride specifically; instead, issuing bodies are procuring naloxone, generic multi-source pharmaceuticals, and related drug deactivation and pharmacy benefit systems. The code shows activity from county health departments, state health and human services agencies, and multistate cooperative purchasing alliances, all seeking to source pharmaceutical products through competitive processes. Work solicited under the nominal code includes community health support (naloxone procurement for overdose response), generic pharmaceutical supply agreements spanning state and local facilities, and exploratory pharmacy direct-contracting initiatives.

Recent activity spans Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with responses due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription programs for state pharmacy benefit management. The nominal UNSPSC code shows marginal alignment with the scope of work actually being procured; the actual buying centers on naloxone, generic pharmaceutical supply chains, and pharmacy program infrastructure rather than chlorphenoxamine hydrochloride as a specified product.